Korea’s drug regulatory body extended the use of a stem cell therapy for COVID-19 for an additional year, allowing local hospitals to use the Pharmicell sponsored investigational regenerative therapeutic regimen. Now the order allows a particular academic medical center’s institutional review board (IRB) to apply for use of the allogeneic mesenchymal stem cell (MSC) therapy. With the regulatory greenlight to use to treat two or more patients, hospitals in Korea seeking to access the therapy for patients need only obtain approval from the hospital’s IRB. Apparently, the regimen has worked well since compassionate use of the regenerative regimen was given the nod in March. Since then, six severe COVID-19 patients have been treated. One patient unfortunately died while five others recovered based on the use of the Pharmicell Cellgram-AKI. In a couple cases, the MSC-based therapy has rapidly healed severely ill COVID-19 patients.
This recent news involves a few different care centers, including Severance Hospital in central Seoul as well as Eunpyeong St. Mary’s Hospital, reports Kim Chan-hyuk with Korea Biomedical Review.
Regenerative Therapy—What is It?
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).